NCT01447706View on ClinicalTrials.gov

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

June 30, 2015

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

MM-121

MM-121 (SAR256212) (IV)

DRUG

Paclitaxel

Standard dosing Paclitaxel (IV)

Trial Locations (10)

28203

Carolinas Medical Center/Blumenthal Cancer Center, Charlotte

37403

Chattanooga GYN Oncology, Chattanooga

43606

ProMedica Health System, Inc., Toledo

46202

Indiana University Simon Cancer Center, Indianapolis

85258

Pinnacle Oncology, Scottsdale

85306

Arizona Center for Cancer Care, Glendale

92056

North County Oncology, Oceanside

92879

Wilshire Oncology Medical Group, Corona

93309

Comprehensive Blood and Cancer Center, Bakersfield

93454

Central Coast Medical Oncology, Santa Maria

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Merrimack Pharmaceuticals

INDUSTRY

NCT01447706 - A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers | Biotech Hunter | Biotech Hunter